Application error: a client-side exception has occurred (see the browser console for more information).

Scientists have revealed how certain immune cells may be quietly helping prostate cancer grow—and how blocking them could help the body fight back.

XTANDI is the first and only androgen receptor pathway inhibitor (ARPI) indicated and reimbursed in Ontario for use in patients with nmCSPC with biochemical recurrence at high risk for ...

Background: Two phase III trials, COMET-1 and COMET-2, have reported that cabozantinib did not extend overall survival (OS) outcomes compared to prednisone and prednisone plus mitoxantrone ...

Berlin: Bayer has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended darolutamide, an oral androgen receptor ...

EMA committee recommends marketing approval for Bayer’s Nubeqa for patients with advanced prostate cancer: Berlin Saturday, June 21, 2025, 10:00 Hrs [IST] The Committee for Medi ...

ORION CORPORATION PRESS RELEASE 20 JUNE 2025 at 13.30 EEST CHMP recommends third indication for darolutamide for patients with advanced prostate cancer CHMP adopts positive opinion for the marketing ...

ASCO 2025 IRONMAN: Can PSA Guide Metastatic Prostate Cancer Care? New findings suggest that a PSA level of 0.2 ng/mL or greater can predict a poor prognosis and indicate a possible need for treatment ...

MSD and Daiichi Sankyo have announced first subject dosing in the randomised IDeate-Prostate01 Phase III trial of ifinatamab ...

Merck and Daiichi Sankyo have announced that the first patient has been dosed in the IDeate-Prostate01 phase 3 trial evaluating the efficacy and safety of investigational ...

Key Takeaways The FDA approved updated labeling for Talzenna plus Xtandi for HRR gene-mutated metastatic castration-resistant prostate cancer, based on the TALAPRO-2 trial results. The TALAPRO-2 trial ...